Introduction
The United Nations World Tourism Organization (UNWTO) reports that the number of people traveling internationally has grown substantially over the past 6 decades -from 25 million in 1950, to 278 million in 1980, 528 million in 1995, and 1,035 million in 2012 [1] . This number is projected to increase by 3.3 % per year between 2010 and 2030, reaching 1.8 billion by 2030. Given these rising numbers, it is critical to consider the variety of health risks associated with international travel. The risk of travel-related infectious disease is contingent upon many factors, such as region of the world, the traveler's age and health status, the duration of travel, and the nature of activities. Environmental factors such as altitude, humidity, temperature, exposure to animals and insects, hygiene, sanitation, and access to clean water also contribute to disease risk. Accordingly, all individuals planning to travel should seek the advice of a health professional to better understand the potential hazards associated with their chosen destination. Pre-travel consultations provide the traveler with steps to undertake before, during, and after travel in order to mitigate disease risk. The World Health Organization (WHO) and the Centers for Disease Control (CDC) have compiled guidelines and information for risk assessment during pre-travel consultations. Effective consultations require careful review of the health background of the traveler and their itinerary, including planned activities [2••, 3••] . Advice to the patient should be personalized, highlighting likely exposure to food-and waterborne infections, vector-borne diseases, respiratory tract infections, and blood-borne infections [2••] . Providing the traveler with written information of items discussed during a pre-travel visit will reinforce critical topics.
Unfortunately, studies have shown that most travelers from the United States and other countries do not seek pre-travel health advice. According to the GeoSentinel and Global TravEpiNet collaborative CDC surveillance systems, less than 50 % of ill travelers reported pre-travel medical visits, although 75 % of planned travel is to malaria-endemic regions [4•, 5•] . The CDC estimates that approximately 4 million travelers to developing regions are ill enough to seek health care, either while abroad or upon returning home [6] . Although there are limitations to these studies, they address the need for more travel medicine clinics around the globe in order to increase access and encourage international travelers to seek pre-travel medical consultation.
This article will discuss some of the most common vaccine-preventable diseases, along with disease distribution, indications and recommendations for travelers, precautions/contraindications, and vaccine administration schedules. Refer to Table 1 
Routine travel vaccines Hepatitis A
Hepatitis A is the most common form of viral hepatitis and the second-most common vaccine-preventable infection in travelers [7, 8] . A recent population-based survey estimated that the highest incidence of disease occurs in East Africa, at 14.1 cases/100,000 person-months [9] . The hepatitis A virus (HAV) is transmitted via fecal-oral route from contaminated food and water or by close contact with infected individuals. Although the risk of contracting the virus is highest for those who live in or visit rural areas, trek in backcountry areas, or frequently eat or drink in settings of poor sanitation, cases of travel-related hepatitis A can occur in travelers in developing countries with "standard" tourist itineraries, accommodations, and eating behaviors [10] . The incubation period for hepatitis A averages 28 days (range, 15-50 days). The disease is most severe in older adults (50+ years). Clinical manifestations include the abrupt onset of fever, malaise, anorexia, nausea, and abdominal discomfort, followed within a few days by jaundice. Africa, South Asia, Central America, and Mexico are the highest-risk areas, but vac- 
Hepatitis B
Hepatitis B virus (HBV) is transmitted by contact with contaminated blood, blood products, and other body fluids. Infection with HBV can cause acute or chronic viral infection of the liver. Chronic infection with HBV puts individuals at higher risk of death from cirrhosis and liver cancer [12] . Hepatitis B virus can cause acute illness, with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. Hepatitis B is most prevalent in subSaharan Africa and East Asia [12] . The risk for HBV infection in travelers may be higher in countries where the prevalence of chronic HBV infection is high or intermediate. Expatriates, missionaries, and long-term development workers in such countries may be at increased risk for HBV infection [12] . Education about the disease and vaccination against HBV should be provided to individuals who are traveling to provide or receive medical care, when travel duration is longer than 4 weeks, and when sexual encounters with new partners may occur abroad. Since risk of developing chronic HBV is highest in young children, travelers born in high HBV-endemic countries may opt to undergo HBV serology to determine need for vaccination.
Indications for travelers
Recommended by the CDC for the following individuals: & Unvaccinated international travelers to regions with high levels of endemic HBV infection and high risk, including: prolonged stays, frequent shorter stays in the same areas, possibility of sexual encounters with new partners while traveling, those with potential to acquire medical care while traveling, health care workers, and those who may acquire tattoos, body piercings, or acupuncture while traveling
Vaccine schedule & 1.0 mL IM in the deltoid muscle at 0, 1, and 6 months; may be accelerated to receive a 3-dose series over 1 month, with a fourth dose at 1 year to ensure long-term protection & Approximately 33 % develop immunity after 1 dose, 66 % after 2 doses; 3 doses required for long-term protection with traditional dosing & Prolonging interval does not require restarting the series. & Serologic testing and booster vaccination are not recommended before travel for immunocompetent adults who have been previously vaccinated [12] .
Vaccine-specific precautions/contraindications
& None
Typhoid fever
Typhoid fever is a potentially severe and life-threatening illness cause by Salmonella enterica serotype Typhi, also referred to as Salmonella typhi. Infection by Salmonella typhi occurs by ingestion of food or water contaminated by the urine or feces of an infected person, making humans the sole source of typhoid fever transmission. The incubation period of typhoid infection is 6-30 days. The onset of illness is gradual, beginning with fatigue and fever that increases daily from low-grade to as high as 102-104°F (38-40°C) by the third to fourth day of illness [13] . Other symptoms include headache, malaise, anorexia, enlarged spleen and liver, and transient macular rash of rose-colored spots occasionally seen on the trunk [13, 14] . The serious complications of typhoid fever generally occur after 2-3 weeks of illness and may include intestinal hemorrhage or perforation, which can be life-threatening [13] . Although the risk of typhoid fever is highest for travelers to southern Asia (6-30 times higher than for all other destinations), other areas of risk include East and Southeast Asia, Africa, the Caribbean, and Central and South America [13] . All travelers, even if vaccinated, should take food and water precautions. ○ The 7-day course must be completed 1 week prior to potential exposure to S. typhi.
Indications for travelers
○ If reimmunization is necessary, the 7-day course must be completed every 5 years when repeated or continued exposure to typhoid fever exists. ○ If reimmunization is necessary due to repeated or continued risk of exposure to S. typhi, another single 0.5 mL dose should be administered if more than 2 years since the previous dose.
Vaccine-specific precautions/contraindications & Ty21a
○ Vaccine is contraindicated in those with immunocompromised conditions and women who are pregnant.
○ Reactions include abdominal pain (6.4 %), nausea (5.8 %), headache (4.8 %), fever (3.3 %), diarrhea (2.9 %), vomiting (1.5 %), and skin rash (1.0 %). & Typhoid Vi inactivated polysaccharide vaccine (Typhim Vi®) ○ Inactivated injectable vaccine is also well-tolerated.
○ Common adverse reactions include localized injection site reactions, including soreness, induration, and erythema. Less common systemic reactions include headache, fever, and malaise.
Special travel vaccines Yellow fever
Yellow fever virus (YFV) transmission occurs via the bite of an infected Aedes aegypti mosquito. Humans and non-human primates serve as reservoirs for the disease. Most cases of YFV infection are asymptomatic or clinically inapparent. For individuals who develop symptomatic illness, the incubation period is typically 3-6 days. The initial illness presents as a nonspecific influenza-like syndrome, with sudden onset of fever, chills, headache, backache, myalgia, prostration, nausea, and vomiting [15] . Most patients improve after the initial presentation, but approximately 15 % of patients progress to a more serious or toxic form of the disease characterized by jaundice, hemorrhagic symptoms, and eventually shock and multisystem organ failure [15] . Yellow fever is endemic in sub-Saharan Africa and tropical South America. A traveler's risk for acquiring yellow fever is determined by various factors, including immunization status, location of travel, season, duration of exposure, occupational and recreational activities while traveling, and local rate of virus transmission at the time of travel [15] . With the exception of the meningococcal vaccine required for the Hajj pilgrimage, the yellow fever vaccination is the only vaccine required to enter endemic countries.
Indications for travelers
& Recommended for persons 9 months of age or older living in or traveling to YFV-endemic areas Travelers to YFV-endemic areas must show proof of vaccination or proof of medical contraindication by means of an international certificate of vaccination or prophylaxis (ICVP). Yellow fever vaccination is carried out for two reasons: (1) to protect the individual in areas where there is a risk of yellow fever infection; and (2) to protect vulnerable countries from importation of the yellow fever virus. Travelers should be vaccinated if they visit a country where there is a risk of exposure to yellow fever. In some non-endemic countries, yellow fever vaccination is a prerequisite for entry for those who have recently passed through yellow fever-endemic areas.
Vaccine schedule
& The 17D yellow fever vaccine is administered subcutaneously as a single 0.5 mL dose. & The vaccine is supplied as a lyophilized powder, and must be reconstituted with the provided sterile diluent just prior to administration. Vaccine ad-ministration must occur within 30 minutes of reconstitution. & The World Health Organization recently released a position statement noting that one-time administration of yellow fever vaccination is probably protective for life; however, at this time, reimmunization is still recommended every 10 years for continued or repeated exposure.
Vaccine-specific precautions/contraindications
& Contraindicated in infants younger than 6 months of age, persons with severe egg allergy or thymus disorders, and those who are immunocompromised & Should be avoided in pregnancy unless the risk of exposure to disease outweighs the risk of adverse effects & Severe adverse effects associated with yellow fever vaccine are yellow fever vaccine-associated neurotropic disease (YEL-AND), which is rarely fatal, and yellow fever vaccine-associated viscerotropic disease (YEL-AVD), which is frequently fatal. In recent years, these effects have rarely been seen in people of all ages, with a higher incidence in individuals 60 years of age and older [15] . The onset of YEL-AND in documented cases is 3-28 days after vaccination, and almost all cases were in first-time vaccine recipients. The rate is higher in people 60 years and older, with a rate of 1.6 /100,000 doses in individuals aged 60-69 years [15] . & For persons at higher risk of serious adverse reactions, if travel cannot be avoided, the decision to vaccinate is based on weighing the risks and benefits of vaccination in the context of destination-specific risk for exposure to YF.
Meningococcal disease
Invasive meningococcal disease in travelers is rare, but its consequences can be devastating [16, 17] . Meningococcal disease is caused by the bacterium Neisseria meningitides, and almost all invasive disease is caused by 1 of the 5 major serogroups: A, B, C, Y, and W-135. Person-to-person transmission occurs by close contact with respiratory secretions or saliva [18] . The incidence of meningococcal disease is highest in the "meningitis belt" of sub-Saharan Africa, an area spanning the continent from Senegal and the Gambia in the west to Ethiopia in the east. The rate of meningococcal disease in this region is several times that of the United States, with epidemics generally occurring during the December-June dry season [18] . The risk of travelers acquiring invasive meningococcal disease appears to be comparatively low [17] . The most significant risk is for travelers to the meningitis belt who have prolonged contact with local populations during an epidemic. The Hajj pilgrimage to Saudi Arabia has been associated with outbreaks of meningococcal disease in returning pilgrims and their household contacts [18] . There have been several significant achievements in the field of meningococcal vaccine development during the past few years [19] . Two tetravalent conjugate vaccines and one tetravalent polysaccharide vaccine are currently available to international travelers and contain serotypes A, C, Y, W135. 
Indications for travelers

Rabies
Rabies is a disease caused by a neurotropic Rhabdoviridae virus present in animal saliva, which is transmitted to humans via a bite or a bleeding scratch. Rabies is nearly 100 % fatal but can be efficiently averted by preexposure prophylaxis (PreP), avoidance of contact with animals, and postexposure prophylaxis (PEP) [20] . More than 55,000 people worldwide die from rabies each year, with 95 % of these deaths occurring in Asia and Africa from a rabid dog bite [21] . The risk of rabies in travelers is proportional to the probability of contact with potentially rabid mammals. In most developing countries, the estimated ratio of dogs (both owned and ownerless) to humans is 1:10, and an average 100 suspected rabid dog bites per 100,000 inhabitants are reported annually [14] . Travelers should avoid contact with animals, primarily warm-blooded mammals. PreP should be considered for travelers with high risk of exposure, including field biologists or veterinarians, spelunkers, and those staying for an extended period of time (especially children) in a high-risk region.
Indications for travelers
& Approved for use in all age groups for PreP and PEP & Recommendations for PreP rabies vaccine are grouped by the CDC into categories of exposure risk, including:
○ 3-dose PreP: continuous (e.g., rabies lab workers), frequent (e.g., wildlife workers), infrequent (e.g., remote-destination travelers without reliable PEP)
○ No vaccine: rare (e.g., most travelers)
Vaccine schedule & Imovax® (human diploid cell vaccine, HDCV)
○ Primary vaccination is 3 doses of 1.0 mL administered intramuscularly, preferably in the deltoid muscle in adults and in the anterolateral part of the thigh in infants and children, on days 0, 7, 21 or 28.
○ Supplied as a vial of freeze-dried vaccine with a syringe containing 1.0 mL of diluent. The vaccine must be reconstituted with the diluent and administered immediately after reconstitution. & RabAvert® (purified chick embryo cell, PCEC) ○ Primary vaccination is 3 doses of 1.0 mL administered intramuscularly, preferably in the deltoid muscle in adults and in the anterolateral part of the thigh in infants and children, on days 0, 7, 21 or 28.
○ Supplied as a lyophilized powder vaccine that should be reconstituted with the supplied diluent and administered immediately after reconstitution The post-exposure dose in previously unvaccinated individuals is 4 doses of 1.0 mL of either product, given on days 0, 3, 7, and 14, with a weight-based dose of rabies immune globulin (RIG), preferably given with the first vaccine dose. In previously vaccinated individuals, 2 doses of either product should be given on days 0 and 3. There is no need for RIG in previously vaccinated individuals.
Vaccine-specific precautions/contraindications
& Pregnancy is not a contraindication to PEP with rabies vaccine.
Poliomyelitis
Poliomyelitis (polio) is caused by the poliovirus, which is ingested through contaminated food or water and spread via fecal-oral route. Polio is a disease of the central nervous system that can cause flaccid paralysis of muscles, respiratory failure, and death. The introduction of the polio vaccine drastically reduced the number of polio cases worldwide, although there has been a reemergence of the disease within the last decade due to reduced vaccination rates in various regions. In 2013, only three countries (Afghanistan, Nigeria, and Pakistan) remained polio-endemic, down from more than 125 in 1988 [22] . In the United States, infants and children should be vaccinated against polio as part of a routine immunization series [23] . Polio vaccination is recommended for all travelers to polio-endemic or epidemic areas [23] . Individuals traveling to areas where poliomyelitis cases are still occurring should ensure that they have completed the recommended age-appropriate polio vaccine series and should be adequately vaccinated with a booster dose if necessary [23] . [24] . The incubation period is 5-15 days, with sudden onset of fever, headache, and vomiting. Mental status changes, focal neurologic deficits, generalized weakness, and movement disorders may develop over the next few days. JE virus is the most common vaccinepreventable cause of encephalitis in Asia (50 % of cases from China) and parts of the western Pacific [25] . Local transmission of JE virus has not been detected in Africa, Europe, or the Americas. Transmission principally occurs in rural agricultural areas, often associated with rice cultivation and flood irrigation, some of which may be near or within urban areas. In temperate areas of Asia, transmission is seasonal, and human disease usually peaks in summer and fall. In the subtropics and tropics, seasonal transmission varies with monsoon rains and irrigation practices and may be prolonged or even occur year-round. The overall risk of JE infection in travelers in endemic areas is low, but travelers or expatriates staying for a prolonged period of time (94 weeks) are at a similar risk of infection from JEV as residents of the area. Even during brief trips, travelers may be at increased risk if they have extensive outdoor or nighttime exposure in rural areas during periods of active transmission [24] . 
Indications for travelers
Routine vaccines in the context of travel Influenza
Respiratory illness, and particularly influenza, is one the most common causes of morbidity in travelers, likely due to close contact with large numbers of people in close quarters, long-haul air travel, and travel to the Northern Hemisphere during November-April [26] . Recent data suggest that influenza is the most common vaccine-preventable disease among travelers, occurring in an estimated There are two subtypes of influenza A (H3N2 and H1N1) and two strains of influenza B (Yamagata and Victoria lineage) currently circulating among humans. Traditionally, seasonal influenza vaccines have been trivalent (two A strains and one B strain). More recently, a quadrivalent vaccine has been approved that includes a second B strain. Two new non-eggbased vaccines have also been introduced: a Madin-Darby canine kidney (MDCK) cell culture-based vaccine and a recombinant hemagglutinin vaccine. Each year, the World Health Organization makes two sets of vaccine recommendations: the first in February for the next Northern Hemisphere winter season (November-April) and another in September for the next Southern Hemisphere winter season (April-October). Although both Northern and Southern Hemisphere vaccines are largely produced in the same multinational manufacturing company plants, the southern vaccine is generally not available in northern countries and vice versa. Avian influenza, often referred to as "bird flu," has not been documented in travelers, and there is no commercial vaccine available. The seasonal influenza vaccine is not expected to provide protection against avian strains. Tetanus, diphtheria, pertussis
Indications for travelers
Tetanus, diphtheria, and pertussis are grouped together here to correspond to the combined vaccine. For travelers, tetanus is extremely rare, while diphtheria and pertussis occur occasionally [4•] . Tetanus is a non-communicable disease acquired through the natural environment, typically through a puncture wound. While the occurrence of tetanus in travelers is rare, the consequences of acquiring it in a developing country with inadequate post-exposure care can be deadly. Unlike rabies, which also rarely occurs but is associated with very high mortality rates, tetanus has an easy one-dose prevention strategy employed routinely in the United States. In the U.S., someone presenting to the emergency department for a tetanus-prone wound would be given a tetanus-containing vaccine if more than 5 years had elapsed since the previous dose. Using this strategy preventatively for travelers, tetanus vaccination should be updated (preferably with combined tetanus, diphtheria and acellular pertussis, Tdap) if more than 5 years have elapsed since the last dose. An adult who has never received an acellular pertussis-containing vaccine should receive Tdap regardless of the length of time since their last tetanus booster. Diphtheria does not occur in the U.S., but it remains endemic in much of the rest of the world, notably in Russia and the countries of the former Soviet Union. Pertussis occurs in outbreaks throughout the U.S. and continues to occur globally. For travelers planning to work with children or to provide healthcare, it should be stressed that they should be immunized against both diphtheria and pertussis not only for their own protection, but also for the young children with whom they interact. 
